NASDAQ:YMTX Yumanity Therapeutics - YMTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Yumanity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.00 -0.83 (-10.60%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.00▼$8.2250-Day Range$1.68▼$7.8352-Week Range$0.95▼$3.78Volume15,023 shsAverage Volume473,083 shsMarket Capitalization$75.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Yumanity Therapeutics (NASDAQ:YMTX) StockYumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More Receive YMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMTX Stock News HeadlinesDecember 26, 2022 | msn.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 20, 2022 | bizjournals.comKineta finalizes reverse merger with Yumanity, secures additional fundingJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 5, 2022 | finance.yahoo.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaDecember 5, 2022 | investorplace.comWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?November 14, 2022 | finanznachrichten.deYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finance.yahoo.comYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 10, 2022 | finance.yahoo.comYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.January 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.August 29, 2022 | finance.yahoo.comYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaAugust 4, 2022 | finance.yahoo.comYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsJune 8, 2022 | finance.yahoo.comInside Kineta's plans after unveiling reverse merger dealJune 7, 2022 | bizjournals.comSeattle biotech Kineta to go public in merger deal with Yumanity TherapeuticsJune 7, 2022 | msn.comShort Volatility Alert: Yumanity Therapeutics, Inc.June 6, 2022 | marketwatch.comYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXJune 6, 2022 | seekingalpha.comYumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26MJune 6, 2022 | nasdaq.comYumanity Therapeutics To Sell 2 Product Candidates For $26 Mln In Cash; Inks Merger Deal With KinetaJune 6, 2022 | finance.yahoo.comYumanity Therapeutics Shares Trading Higher Today - Read Here WhyJune 6, 2022 | investorplace.comWhy Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?June 6, 2022 | finance.yahoo.comYumanity Therapeutics Announces Definitive Agreements for Two Strategic TransactionsJune 2, 2022 | benzinga.com53 Stocks Moving In Thursday's Mid-Day SessionMay 14, 2022 | seekingalpha.comYumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02MMay 13, 2022 | finance.yahoo.comYumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2022 | finance.yahoo.comYumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsMarch 25, 2022 | benzinga.comLooking Into Yumanity Therapeutics's Return On Capital EmployedMarch 24, 2022 | seekingalpha.comYumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04MMarch 24, 2022 | finance.yahoo.comYumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate DevelopmentsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive YMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMTX Company Calendar Last Earnings8/12/2021Today1/28/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:YMTX CUSIPN/A CIK1445283 Webwww.yumanity.com Phone(617) 409-5300FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,500,000.00 Net Margins-660.61% Pretax Margin-660.61% Return on Equity-263.34% Return on Assets-107.08% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.21 Sales & Book Value Annual Sales$8.04 million Price / Sales9.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book3.07Miscellaneous Outstanding Shares10,856,000Free Float9,504,000Market Cap$75.99 million OptionableNot Optionable Beta0.32 Key ExecutivesDr. Richard Peters M.D. (Age 59)Ph.D., CEO, Pres & Director Comp: $896.1kDr. Vikram Khurana M.D.Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery BiologyMs. Chee Yeun Chung Ph.D.Scientific Co-Founder & Associate Director of Discovery BiologyMs. Marie Epstein CPAVP of Fin.Mr. Michael D. Wyzga (Age 33)SVP, CFO & Treasurer Mr. Devin Whittemore Smith (Age 54)SVP, Gen. Counsel & Sec. More ExecutivesKey CompetitorsRezoluteNASDAQ:RZLTLongboard PharmaceuticalsNASDAQ:LBPHSELLAS Life Sciences GroupNASDAQ:SLSNuCanaNASDAQ:NCNAInozyme PharmaNASDAQ:INZYView All CompetitorsInsiders & InstitutionsRichard PetersSold 10,890 sharesTotal: $18,404.10 ($1.69/share)Michael D WyzgaSold 3,116 sharesTotal: $5,266.04 ($1.69/share)Vanguard Group Inc.Sold 22,612 shares on 11/15/2022Ownership: 2.417%Citadel Advisors LLCBought 17,364 shares on 11/15/2022Ownership: 0.456%Richard PetersSold 4,584 sharesTotal: $8,480.40 ($1.85/share)View All Insider TransactionsView All Institutional Transactions YMTX Stock - Frequently Asked Questions How have YMTX shares performed in 2023? Yumanity Therapeutics' stock was trading at $6.35 at the start of the year. Since then, YMTX shares have increased by 10.2% and is now trading at $7.00. View the best growth stocks for 2023 here. When is Yumanity Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our YMTX earnings forecast. How were Yumanity Therapeutics' earnings last quarter? Yumanity Therapeutics, Inc. (NASDAQ:YMTX) announced its quarterly earnings data on Thursday, August, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.19. The firm earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%. What is Yumanity Therapeutics' stock symbol? Yumanity Therapeutics trades on the NASDAQ under the ticker symbol "YMTX." How do I buy shares of Yumanity Therapeutics? Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Yumanity Therapeutics' stock price today? One share of YMTX stock can currently be purchased for approximately $7.00. How much money does Yumanity Therapeutics make? Yumanity Therapeutics (NASDAQ:YMTX) has a market capitalization of $75.99 million and generates $8.04 million in revenue each year. The company earns $-39,500,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis. How can I contact Yumanity Therapeutics? Yumanity Therapeutics' mailing address is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. The official website for the company is www.yumanity.com. The company can be reached via phone at (617) 409-5300 or via email at lroth@burnsmc.com. This page (NASDAQ:YMTX) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.